Telenzepine

Overview of the antimuscarinic drug Telenzepine

Telenzepine
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Telenzepine is a pharmacological agent classified as an antimuscarinic drug. It is primarily used in the treatment of gastrointestinal disorders due to its ability to selectively inhibit muscarinic receptors in the gastrointestinal tract.

Mechanism of Action

Telenzepine functions by selectively blocking the M1 subtype of muscarinic receptors. These receptors are predominantly located in the central nervous system and the gastrointestinal tract. By inhibiting these receptors, telenzepine reduces gastric acid secretion, making it effective in the management of peptic ulcer disease.

Pharmacokinetics

Telenzepine is administered orally and is absorbed through the gastrointestinal tract. It undergoes hepatic metabolism and is excreted primarily via the renal system. The drug has a moderate half-life, allowing for convenient dosing schedules in clinical practice.

Clinical Uses

Telenzepine is used in the treatment of conditions such as:

• Peptic ulcer disease
• Gastroesophageal reflux disease (GERD)
• Functional dyspepsia

Its selective action on M1 receptors makes it a preferred choice in patients where reduction of gastric acid secretion is desired without significant systemic side effects.

Side Effects

Common side effects of telenzepine include:

• Dry mouth
• Constipation
• Blurred vision

These side effects are typical of antimuscarinic agents due to their action on muscarinic receptors in various parts of the body.

Related pages

• Antimuscarinic
• Muscarinic acetylcholine receptor
• Peptic ulcer disease

• 

  Telenzepine